September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
20 citations
,
January 2003 in “Chemical and Pharmaceutical Bulletin” The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.
November 2024 in “Nanomaterials” The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.
15 citations
,
November 1983 in “British journal of dermatology/British journal of dermatology, Supplement” Testosterone increases hamster hair growth; cyproterone acetate reduces it.
August 2002 in “Inpharma Weekly” 
35 citations
,
February 1994 in “Fundamental and applied toxicology” High doses of finasteride cause cell growth and tumors in mice.
47 citations
,
October 2016 in “Molecular and Cellular Endocrinology” Androgens prevent hair growth by changing Wnt signals in cells.
58 citations
,
March 2006 in “Current topics in medicinal chemistry” Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.
2 citations
,
February 2007 in “PubMed” Dutasteride is cheaper than finasteride for treating benign prostatic hyperplasia.
March 2016 in “European Urology Supplements” Methylation in specific gene region causes finasteride resistance in some BPH patients.
22 citations
,
March 2012 in “Molecular Medicine Reports” DHT affects hair follicle cells by changing microRNA levels, leading to less cell growth and more cell death.
DHT, not testosterone, mainly affects hair growth and related conditions.
9 citations
,
January 2009 in “PubMed” Finasteride treatment can decrease certain steroids and increase others, possibly leading to depression symptoms in some cases.
1 citations
,
June 2015 in “Cancer” Finasteride and dutasteride may lower melanoma risk, with teenage acne possibly indicating higher risk.
1040 citations
,
October 1992 in “The New England Journal of Medicine” Finasteride effectively treats BPH but may increase sexual dysfunction risk.
January 2004 in “Elsevier eBooks” Anti-androgen drugs can treat conditions like prostate cancer and male pattern baldness by blocking effects of testosterone and DHT.
1 citations
,
October 2013 in “Urology” More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.
January 2004 in “DOAJ (DOAJ: Directory of Open Access Journals)” Men with androgenetic alopecia do not have elevated DHEA-S levels.
23 citations
,
January 2020 in “Frontiers in Pharmacology” Dihydrotestosterone affects hair growth by changing the Wnt/β-catenin pathway, with low levels helping and high levels hindering growth.
September 2004 in “Urology” Finasteride may reduce prostate cancer risk.
August 2025 in “Therapeutics” Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.
27 citations
,
July 2008 in “The Journal of Steroid Biochemistry and Molecular Biology” The new compounds may be more effective and cheaper than current treatments for conditions like baldness.
61 citations
,
September 1994 in “The Journal of Clinical Endocrinology and Metabolism” 
March 2012 in “Dermatology Times E-News” Men with pattern baldness may have a higher risk of prostate issues.
April 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Chronic use of 1 mg/day finasteride for hair loss may delay prostate cancer diagnosis by lowering PSA levels.
13 citations
,
September 2017 in “Life sciences” Androgens may influence bladder cancer progression by affecting cellular behavior.
190 citations
,
October 2002 in “The FASEB journal” Androgens may cause hair loss by increasing TGF-beta1 from scalp cells, which inhibits hair cell growth.